SEAGULL HEALTH
Your health,We care!
Tunlametinib Capsules are the world's first and only approved targeted drug for advanced melanoma with NRAS mutation that has failed anti-PD-1/PD-L1 therapy, featuring convenient oral administration, controllable safety and definite efficacy.
AuthenticGuaranteeFast DeliveryPrivacy On March 15, 2024, the National Medical Products Administration (NMPA)
granted conditional approval for the marketing of Turalutinib Capsules.
On March 15, 2024, the National Medical Products Administration (NMPA) granted conditional approval for Tunlametinib Capsules (brand name: Keluping), ···【Read More】
Update: 12 Feb,2026Source: Haiou HealthViews: 109
Copyright 2024 @ haiouhealth.com All right reserved Seagull health | Bigbear Pharmaceutical | Lucius Pharmaceuticals | 老挝全球药房
